Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 11, Number 10—October 2005

Research

Antibacterial Cleaning Products and Drug Resistance

Allison E. Aiello*Comments to Author , Bonnie Marshall†, Stuart B. Levy†, Phyllis Della-Latta‡, Susan X. Lin‡, and Elaine Larson‡
Author affiliations: *University of Michigan School of Public Health, Ann Arbor, Michigan, USA; †Tufts University School of Medicine, Boston, Massachusetts, USA; ‡Columbia University, New York, New York, USA

Main Article

Figure A1

Proportion of study participants with gram-negative bacteria resistant to antimicrobial agents, methicillin-resistant Staphylococcus aureus (MRSA), and methicillin-resistant, coagulase-negative staphylococci (MRCNS). For A and B, Acinetobacter baumanii and A. lwoffi were combined to represent Acinetobacter spp. For C and D, Enterobacter cloacae and E. agglomerans were combined to represent Enterobacter spp. IPM, imipenem; GEN, gentamicin; CIP, ciprofloxacin; AMK, amikacin; CAZ, ceftazidime; TIM,

Figure A1. Proportion of study participants with gram-negative bacteria resistant to antimicrobial agents, methicillin-resistant Staphylococcus aureus (MRSA), and methicillin-resistant, coagulase-negative staphylococci (MRCNS). For A and B, Acinetobacter baumanii and A. lwoffi were combined to represent Acinetobacter spp. For C and D, Enterobacter cloacae and E. agglomerans were combined to represent Enterobacter spp. IPM, imipenem; GEN, gentamicin; CIP, ciprofloxacin; AMK, amikacin; CAZ, ceftazidime; TIM, ticarcillin-clavulanic acid; SXT, trimethoprim-sulfamethoxazole; CRO, ceftriaxone; TZP, piperacillin-tazobactam.

Main Article

TOP